Decreased vitamin D levels have been associated with prostate cancer, but it is unclear whether this association is causal. A functional single-nucleotide polymorphism (SNP) in the group-specific component (GC) gene (T > G, rs2282679) has been associated with 25-hydroxy (25-OH) vitamin D and 1.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
25 dihydroxy (1 25-OH2) vitamin D levels
To examine the hypothesized inverse relationship between vitamin D status and prostate cancer, we studied the association between this SNP and prostate cancer outcome in the prospective PROCAGENE study comprising 702 prostate cancer patients with a median follow-up of 82 months
GC rs2282679 genotypes were not associated with biochemical recurrence [hazard ratios (HR) 0 91, 95 % confidence interval (CI) 0 73-1 12; p = 0 36], development of metastases (HR 1 20, 95 % CI 0 88-1 63; p = 0 25) or overall survival (HR 1 10; 95 % CI 0 84-1 43; p = 0 50)
A causal role of vitamin D status, as reflected by GC rs2282679 genotype, in disease progression and mortality in prostate cancer patients is unlikely
World journal of urology 2015 Jul 25 [Epub ahead of print]
Olivia Trummer, Uwe Langsenlehner, Sabine Krenn-Pilko, Thomas R Pieber, Barbara Obermayer-Pietsch, Armin Gerger, Wilfried Renner, Tanja Langsenlehner
Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Graz, Austria